Steffen Leusmann

Steffen Leusmann

Auto-generated profile, based on publicly available information

Steffen Leusmann

Chemische Biologie der Kohlenhydrate (CBCH), Helmholtz‐Institut für Pharmazeutische Forschung Saarland (HIPS), Helmholtz‐Zentrum für Infektionsforschung 66123 Saarbrücken Deutschland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
SLSteffen Leusmann
Steffen Leusmann
PMPetra Ménová
Petra Ménová
ESElena Shanin
Elena Shanin
ATAlexander Titz
Alexander Titz
CRChristoph Rademacher
Christoph Rademacher
Carbohydrates are essential mediators of many processes in health and disease. They regulate self-/non-self- discrimination, are key elements of cellular communication, cancer, infection and inflammation, and determine protein folding, function and life-times. Moreover, they are integral to the cellular envelope for microorganisms and participate in biofilm formation. These diverse functions of carbohydrates are mediated by carbohydrate-binding proteins, lectins, and the more the knowledge about the biology of these proteins is advancing, the more interfering with carbohydrate recognition becomes a viable option for the development of novel therapeutics. In this respect, small molecules mimicking this recognition process become more and more available either as tools for fostering our basic understanding of glycobiology or as therapeutics. In this review, we outline the general design principles of glycomimetic inhibitors (Section 2). This section is then followed by highlighting three approaches to interfere with lectin function, i.e. with carbohydrate-derived glycomimetics (Section 3.1), novel glycomimetic scaffolds (Section 3.2) and allosteric modulators (Section 3.3). We summarize recent advances in design and application of glycomimetics for various classes of lectins of mammalian, viral and bacterial origin. Besides highlighting design principles in general, we showcase defined cases in which glycomimetics have been advanced to clinical trials or marketed. Additionally, emerging applications of glycomimetics for targeted protein degradation and targeted delivery purposes are reviewed in Section 4.

2 November 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
SLSteffen Leusmann
Steffen Leusmann
ESEike Siebs
Eike Siebs
SKSakonwan Kuhaudomlarp
Sakonwan Kuhaudomlarp
AVAnnabelle Varrot
Annabelle Varrot
AIAnne Imberty
Anne Imberty
ATAlexander Titz
Alexander Titz
The notorious pathogen Pseudomonas aeruginosa relies on the lectin LecA for host cell adhesion, invasion, and biofilm formation. Motivated by the pressing need for new anti‐infective therapies caused by antimicrobial resistance, inhibitors of LecA are under investigation. Complementary to the use of carbohydrate‐based inhibitors, we have previously identified catechols as weak but specific ligands of LecA, constituting a novel class of non‐carbohydrate glycomimetics. By growing the initial millimolar fragment hits, we identified Tolcapone as a promising compound. To gain insight into the structure‐activity relationship (SAR) of catechols as LecA binders, more than 3,200 compounds of the Roche in‐house library were experimentally screened in a competitive binding assay at three concentrations. Of these, 48 compounds were chosen for further investigation, resulting in compounds equipotent to aryl galactosides, the current epitome of LecA inhibition. X‐ray crystallography and saturation transfer difference (STD) NMR spectroscopy revealed conserved interactions of the catechol moiety in the glycan binding site of LecA and rationalized the observed SAR. Our findings demonstrate that it is possible to develop potent non‐carbohydrate glycomimetic lectin inhibitors. This work paves the way for a new avenue of research towards innovative anti‐infective drugs. In a more general perspective, such small molecules also hold potential to challenge the hegemony of antibodies for lectin inhibition in clinical use.

2 November 2025 in Angewandte Chemie
Verified
Journal Article
Open access
SLSteffen Leusmann
Steffen Leusmann
ESEike Siebs
Eike Siebs
SKSakonwan Kuhaudomlarp
Sakonwan Kuhaudomlarp
AVAnnabelle Varrot
Annabelle Varrot
AIAnne Imberty
Anne Imberty
ATAlexander Titz
Alexander Titz
Zusammenfassung: Der berüchtigte Krankheitserreger Pseudomonas aeruginosa ist für die Adhäsion an Wirtszellen, deren Invasion sowie für die Biofilmbildung auf das Lektin LecA angewiesen. Angesichts des dringenden Bedarfs neuer antiinfektiver Therapien infolge antimikrobieller Resistenzen sind LecA‐Inhibitoren Gegenstand aktueller Forschung. Ergänzend zu kohlenhydratbasierten Inhibitoren hatten wir Catechole (dt. Brenzkatechine) als schwache, aber spezifische LecA‐Liganden identifiziert, welche eine neuartige Klasse der nicht‐kohlenhydratbasierten Glykomimetika darstellen. Hier berichten wir zum Catechol Tolcapon sowie zu dessen Derivaten als neuer Klasse potenter Glykomimetika. Durch die Weiterentwicklung der anfänglich millimolaren Hit‐Fragmente konnten wir Tolcapon als vielversprechende Verbindung identifizieren. Um Einblicke in die Struktur‐Wirkungs‐Beziehung (SAR) von Catecholen als LecA‐Liganden zu gewinnen, wurden mehr als 3.200 Substanzen der unternehmenseigenen Roche‐Bibliothek in einem kompetitiven Bindungsassay bei drei Konzentrationen experimentell getestet. Von diesen wurden 48 Verbindungen für weiterführende Untersuchungen ausgewählt, was zur Identifizierung von Substanzen führte, die ebenso potent wie Arylgalaktoside sind, welche derzeit als Goldstandard der LecA‐Inhibition gelten. Röntgenkristallographie und Sättigungstransfer‐Differenz (STD) NMR‐Spektroskopie zeigten konservierte Wechselwirkungen des Catecholmotivs in der Kohlenhydrat‐Bindetasche von LecA und konnten die beobachtete SAR rational erklären. Unsere Ergebnisse belegen die Machbarkeit der Entwicklung von potenten, nicht‐kohlenhydratbasierten glykomimetischen Lektin‐Inhibitoren. Diese Ergebnisse ebnen den Weg einer neuen Forschungsrichtung, die innovative Antiinfektiva hervorbringen könnte. Im weiteren Sinne haben solch kleine Moleküle das Potenzial, die Vorherschaft von Antikörpern bei der Lektin‐Inhibition in der klinischen Anwendung herauszufordern.